Operating EBITDA for existing centers was Rs 779 mn, a growth of 19 per cent year-on-year, reflecting an Operating EBITDA margin of 18 per cent
HealthCare Global Enterprises Limited (“HCG”) has announced its financial results for the quarter (“Q3”) and nine months ended December 31st, 2022.
Highlights for quarter ended December 31st, 2022
- Consolidated Income from Operations (“Revenue”) was Rs 4,247 mn as compared to Rs 3,581 mn in the corresponding quarter of the previous year, reflecting a year-on-year growth of 19 per cent
- Consolidated Profit Before Depreciation and Amortization, Finance Costs, Exceptional Items and Taxes (“EBITDA”) was Rs 812 mn, as compared to Rs 636 mn in the corresponding quarter of the previous year, a growth of 28 per cent year-on-year and 0 per cent
- Consolidated Profit Before Other Income, Depreciation and Amortization, finance costs, exceptional items and taxes (“Operating EBITDA”), was Rs 755 mn, as compared to Rs 619 mn in the corresponding quarter of the previous year, a growth of 22 per cent year-on-year
- Operating EBITDA for Existing centers was Rs 779 mn, a growth of 19 per cent year-on-year, reflecting an Operating EBITDA margin of 18 per cent
- Operating EBITDA from new centers was Rs 78 mn, as compared to Rs 76 mn in the corresponding quarter of the previous year
- Consolidated Profit after Taxes and Minority Interest (“PAT”) was a profit of Rs 75 mn, as compared to loss of Rs 458 mn in the corresponding quarter of the previous year
Business updates for Q3 FY23
Clinical highlights
- Profiled 1,500+ patients with variety of malignancies using targeted deep sequencing for hotspot mutations in 56/152 cancer related genes.
- 2 of our clinicians at the COE in Bangalore have been named in prestigious National Cancer Institute of USA as working committee members in the RAD immune division.
- Ahmedabad center has performed 700+ Uro oncology procedures, through robotic technique
- Performed 4,200+ cyberknife cases at our COE in Bangalore till date – largest volume by a center in the country.
- Performed 20 cases of adaptive therapy through our recently introduced latest radiation technology “Ethos” in first 3 months.
- Performed 13 complex (“Partial T cell Depleted c19 and tcr alpha beta depleted transplant”) bone marrow transplant through advanced clinimacs technology at our centre in Kolkata in last 18 months – unique capability in East India.